Facile Therapeutics

Facile Therapeutics is developing Ebselen as a treatment for Clostridium difficile (C diff) infection. One of Facile’s founders, Dr. Matthew Bogyo of Stanford, has discovered that the drug Ebselen is effective in resolving the effects of CDI in a mouse model of the disease. An exciting aspect of this discovery is that Ebselen has already been shown to be safe in humans.